PVD (PVDrilling) Company Visit October 2011
|
|
- Diana Harmon
- 5 years ago
- Views:
Transcription
1 PVD (PVDrilling) Company Visit October Preview: 3Q11 EBT margin is expected to be higher than 2Q11 largely due to no booking of provision for Science and Technology Development Fund According to PVD s management, PVD achieved VND2,299bln in revenue and VND293.9bln in NPAT in 3Q11, representing 6.5% and 0.3% yoy growth respectively. Thus, after 9 months of 2011, with respective accumulative sales and NPAT of VND6450bln and VND820bln, PVD already completed 80.6% and 91.1% its 2011 sales and NPAT plans. While the detail figures have not been provided, we speculate that the improved NPAT margin in 3Q11 (12.8%) compared to that of 2Q11 (10.9%) could be largely attributed to the fact that PVD was not supposed to book any provision for the Science and Technology Development Fund in 3Q11, which is booked every 6 months as 10% of the EBT. 4Q11: TAD runs from Oct 15; only two leased rigs will be in used; and EBIT margin is to decline due to higher administration costs related to the settlement of new rig and provision for Science and Technology Development Fund TAD rig: As far as we are concerned, the TAD rig, which is on schedule to be used at the Bien Dong JOC on the Hai Thach and Moc Tinh gas discoveries in Blocks5-2/5-3 offshore Vietnam, was already deployed by Oct 15. With around 77 days in operation till 2011 year end and 97% expected utilization rate, we forecast that PVD s 4Q11 top line could be added by VND318.5bln. Leased rig: However, what is gained from TAD in 4Q11 will be made up for the loss from losing one of its leased fleet in the last quarter of the year. According to PVD s management, the lease contract over the Aquamarine Driller 1
2 with Salamander was renewed only until Oct Therefore, in our valuation model, we only took into consideration two of its leased fleet as follow: Day rate Est. 4Q11 Revenue Rig Client Start End (USD/day) (VND bln) Maersk Convincer Phu Quy JOC 120,000 Nov 2010 Nov Key Hawaii PVEP 119,000 Sep 2011 Nov Source: Company data, SSIResearch estimate, Oct 2011 High SG&A expense with impact on EBIT margin: Historical observation showed that whenever PVD brings a new rig into operation, some sort of settlement costs would incur. Such costs, the breakdown of which is unknown to us, may be pretty big, ranging from VND20bln to VND40bln. For the time being, we speculate that around VND30bln in cost may also incur in 4Q11 when PVD brings TAD rig into operation. In addition, since 4Q10, on semi-annual basis, PVD will book provision for Science and Technology Development fund as 10% of the total 6-month earnings before tax. Based on our estimated PVD s 2H11 earnings before tax, we expect that around VND57bln will be added into administration expense in 4Q11 as provision expense, lifting the Administration expense/sales to 8.9% compared to 8.7% in 3Q11 and 4% in 1Q11. Based on the above assumptions, we expect that for this whole year, PVD may achieve VND9,144bln (21% yoy growth) in sales and VND1,068bln (20.5% yoy growth) in net profit attributable to equity holders of the parent company, translating into an EPS of VND5,075/share, up 21.1% yoy Outlook: Significant NPAT growth of ~49% expected from operation of TAD The possibility of PVD III rig to be re-leased by end of 2011 is high Rig Type W.D (Ft) Clients Day rate Start date End date PVD I IC 300 Hoang Long JOC 125,000 Oct 2011 Jun 2012 PVD II IC 400 Dai Hung PVEP POC 124,000 Jul 2011 June 2012 PVD III IC 400 VietsovPetro 124,000 Jan 2011 Dec 2011 Source: Company data, SSI Research estimate, Oct 2011 By end of 2011, the contract on PVD III with VietsovPetro will come to end. Though it is now being uncertain to us whether PVD III will be renewed or will be resigned with another client, we are convinced that the possibility that PVD III will be leased is high, taking into consideration (i) the average demand for rigs in Bien Dong is about 10 rigs/year and (ii) the number of rigs which are in operation domestically is
3 No Name Of Unit Type Drilling Contractor Owner / Block 1 Ocean General Semisub Diamond Offshore Santos Maersk Convincer Jack Up Rig Maersk Drilling Phu Quy POC 3 PV Drilling I Jack Up Rig PV Drilling Hoang Long JOC 4 PV Drilling II Jack Up Rig PV Drilling Dai Hung 05.1a 5 Galveston Key Jack Up Rig Transocean Cuu Long JOC 6 Ensco 107 Jack Up Rig Ensco Premier Oil 12W 7 Ensco 105 Jack Up Rig Ensco PM3-CAA 8 Key Hawaii Jack Up Rig Transocean PVEP POC 9 PV Drilling III Jack Up Rig PV Drilling VietsovPetro Source: 14 Oct 2011 and is expected to have stable day rate. Also, the day rate is expected remain at around USD 120,000-USD125,000/day. In comparison with SE Asia average day rates for Jackups with WD of over 300 ft.(usd130,897/day), PVD s are 4.7% lower. TAD rig: in full operation with at least one-year guarantee 3
4 When TAD operates in full in 2012 at a fixed 5-year day rate of USD205,000/day, we expect that it would add VND1,585bln in revenue and VND268bln in net profit. As PVD owns 62% of the rig, around VND167bln in NPAT will be added to PVD s bottom line after deducting for minority interest. As investors are already aware of the fact that TAD is operating adjacently to the territorial-conflict zone between Vietnam and China, in the leasing contract over the TAD rig, there is already one term indicating that PVD will receive at least one-year payment for TAD since the date of ceasing TAD operation if any disputes arise. TAD: favorable tax treatment as being classified as high-tech rig At the moment, PVD expects to depreciate TAD rigs in 20 years (similar to PVD II and PVD III) though according to accounting policy, straight line depreciation in 7-10 years is being regulated for drilling machineries. Also, according to PVD s management, as being categorized as high tech rig, TAD will be subject to 10% CIT in the first 15 years. Also, TAD will be exempted from CIT tax for the first 4 years since operation and then 9 years later at 50% of 10% CIT. Gross profit margin: to improve due to lower proportion of leased rigs in total revenue Since it is rather challenging to forecast revenues for PVD s leased fleet as it depends largely on spot demand and whether PVD could lease from any other owner at any point of time for re-leasing purposes. Thus, for the time being, we expect only two leased rigs will be operating and revenue comes in will be VND1,244bln (12.5% total revenue) compared to estimated ~20.6% in As the gross profit margin for leased fleet is moderate at 7-8%, we expect that its decreasing proportion in total revenue in 2012 will boost 2012 gross profit margin 28.3% from 22.2% in Overall CIT may lift up in 2012 While TAD enjoys 0% CIT tax in 2012, from 2012, some of CIT privilege that PVD is enjoying will come to end, lifting up the overall CIT that the company may have to pay on its EBT, in particular Units Current CIT 2012 CIT PVD I, PVD II 0% 12.5% PVD Offshore 12.5% 25% PVD Training 12.5% 12.5% PVD Tech Operating activities 0% 0% Services activities 0% 5% Est. effective tax rate ~12.5% Source: Company data, SSI Research estimate, Oct
5 Tender Barge: pressure on financial expenses in 2012 According to PVD s management, PVD already arranges the USD120bln loans for the building of a tender barge (TB) with PV Ship Yard. This TB will be used for Chevron s drilling activities which last for almost 20 years ahead. This investment is recently known to be a BCC (similar to TAD s case) in which PVD owns 51%, the rest belongs to Seadrill (49%). Once completed, PVD is expected to consolidate 51% of Tender Barge into its FS. Since the information rated to the interest rate and disbursement procedure currently remain unknown to us, we have not taken into account the effects of this loans on PVD s loan and interest schedule for 2012 and thereafter. Based on the above analysis and assumptions, we expect that PVD will be able to achieve VND10,151bln (11% yoy growth) in net sales and VND1,635bln (49% yoy growth) in net earnings after minority interest, which translate into an EPS of VND7,120 in 2012, up 40.3% yoy. Investment view 2009A 2010A 2011E 2012E Net sales 4,096,780 7,572,009 9,143,701 10,150,507 Gross profit 1,239,991 1,757,977 2,027,350 2,872,637 Operating profit (EBIT) 965,891 1,305,291 1,382,859 2,157,026 Earnings before income tax provision 925,935 1,018,629 1,223,533 1,985,229 Net earnings 817, ,542 1,068,371 1,634,675 EPS 3,870 4,190 5,075 7,120 Source: Company data, SSIResearch Estimate, Oct 2011 While fundamentals of the sector has not changed much, we have revised our estimates in accordance with the above updates on the TAD, company s expense and CAPEX plan (investment of new Tender Barge). Overall, amid economic difficulties, PVD still enjoys strong growth in both revenue and bottom line with more impressive growth expected in 2012 than Our estimated 12-month forward EPS for PVD is now at VND6,608/share. Our 1-year target price for PVD stock is VND49,564/share, 29.1% higher than the current price of VND38,400/share. Therefore, we maintain BUY recommendation for PVD stock. Besides, as PVD is capital-intensive company, we pay attention to market value of its rigs in comparison with investment cost. According to the management, the current replacement costs for its three rigs is around USD220bln on average, higher than the investment cost for PVD 1 USD 114bn operational from 2007 and similar to the investment cost of PVD II & PVD III(215bln and 225bln respectively). 5
6 RATING Within 12-month horizon, SSIResearch rates stocks as either BUY, HOLD or SELL determined by the stock s expected return relative to the market required rate of return, which is 22% (*). A BUY rating is given when the security is expected to deliver absolute returns of 22% or greater. A SELL rating is given when the security is expected to deliver returns below or equal to negative 10%, while a HOLD rating implies returns between negative 10% and 22%. *The market required rate of return is calculated based on 1-year Vietnam government bond yield and market risk premium derived from using Relative Equity Market Standard Deviations method. Our rating bands are subject to changes at the time of any significant changes in the above two constituents. DISCLAIMER The information, statements, forecasts and projections contained herein, including any expression of opinion, are based upon sources believed to be reliable but their accuracy completeness or correctness are not guaranteed. Expressions of opinion herein were arrived at after due and careful consideration and they were based upon the best information then known to us, and in our opinion are fair and reasonable in the circumstances prevailing at the time. Expressions of opinion contained herein are subject to change without notice. This document is not, and should not be construed as, an offer or the solicitation of an offer to buy or sell any securities. SSI and other companies in the SSI and/or their officers, directors and employees may have positions and may affect transactions in securities of companies mentioned herein and may also perform or seek to perform investment banking services for these companies. This document is for private circulation only and is not for publication in the press or elsewhere. SSI accepts no liability whatsoever for any direct or consequential loss arising from any use of this document or its content. The use of any information, statements forecasts and projections contained herein shall be at the sole discretion and risk of the user. CONTACT INFORMATION Phuong Hoang Director, Institutional Research & Investment Advisory phuonghv@ssi.com.vn Nga Nguyen Research Analyst ngan@ssi.com.vn SAIGON SECURITIES INC. Member of the Ho Chi Minh Stock Exchange, Regulated by the State Securities Commission HO CHI MINH CITY 72 Nguyen Hue Street, District 1 Ho Chi Minh City Tel: (848) Fax: (848) info@ssi.com.vn HA NOI 1c Ngo Quyen Street Ha Noi City Tel: (848) Fax: (848)
Korean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationASL MARINE. DBS Vickers Pulse of Asia Roadshow 10 January 2012
ASL MARINE DBS Vickers Pulse of Asia Roadshow 10 January 2012 Presentation Outline Group Overview 1Q FY2012 Financial Review (3 months ended 30 September 2011) Operations Review - Shipbuilding - Shiprepair
More information1Q 2009 Results Presentation. 12 May 2009
1Q 2009 Results Presentation 12 May 2009 1 Broadcasting 2 MEDIASET 2009 1Q Total Audience TOTAL AUDIENCE (Jan-Mar) * Individuals Δ vs. 2008 +5.3% 15-64 years +5.6% 1Q TV CONSUMPTION (2000-2009) Average
More informationSmall-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK
Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final
More information2010 First Quarter Results Presentation. 11 th May 2010
2010 First Quarter Results Presentation 11 th May 2010 1 Broadcasting 2 ITALY TV Consumption trend (2003-2010) Average Daily minutes 271 273 270 270 Individuals 269 266 255 250 251 245 251 256 245 244
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK
Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set
More informationSmall-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK
Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationSmall-Cap Research. Celator Pharma (CPXX-NASDAQ)
Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More information1Q 2008 Results Announcement 24 April, 2008 Scope of Briefing
1Q 2008 Results Announcement 24 April, 2008 1 Scope of Briefing Address by Executive Chairman Group Financial Highlights Business Review & Outlook 2 1 Address By Executive Chairman 3 A Tough Year Ahead
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More information22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016
Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationCorcept Therapeutics, Inc.
March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationSmall-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA
Small-Cap Research March 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationCASTOR SEED SEASONAL REPORT
August 3 rd, 2011 CASTOR SEED SEASONAL REPORT Higher area under castor across major castor growing regions in India by around 15% might be a hurdle for price rise in castor seed. Weakened export demand
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More information22nd Century Group, Inc. (XXII - $ Buy)
Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com
More informationOrexigen Therapeutics, Inc.
February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA
More informationMDxHealth. Strong outlook for Research Note.
Research Note MDxHealth Strong outlook for 2017 Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 23 February
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2017 artnet AG Quarterly Interim Statement for the First Quarter of 2017
Quarterly Interim Statement for the First Quarter of 2017 Quarterly Interim Statement for the First Quarter of 2017 Table of Contents General Information and Business Activities Economic Development of
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationZacks Small-Cap Research
Zacks Small-Cap Research October 26, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 CytoSorbents Corporation (CTSO-NASDAQ) CTSO: Additional
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationNORTH AMERICAN DERMATOLOGY. M&A Activity and Valuation Trends Q Robert Ullman Managing Director
Robert Ullman Managing Director rullman@dinancapital.com 45.63.44 NORTH AMERICAN DERMATOLOGY M&A Activity and Valuation Trends Q4 205 William Downing Director wdowning@dinancapital.com 602.734.0682 Michael
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationBrookings Institution, March 4, 2013 Laura Papi and IMF India Team
Brookings Institution, March, 13 Laura Papi and IMF India Team The views expressed in this presentation are those of the authors and should not be attributed to the International Monetary Fund, its Executive
More informationChina Insulin Industry Report, Jan. 2011
China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More informationSmall-Cap Research. Delmar Pharma (DMPI-OTCQB)
Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal
More informationMYnd Analytics, Inc. Update. Midtown Partners Research. Mental Health November 28, 2017
Mental Health November 28, 2017 MYnd Analytics, Inc. OTC MYND We believe MYnd Analytics is commercializing a very valuable predictive technology in a field of medicine, mental disorders, where desicisions
More informationThese Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017.
Rules of Membership 1. Introduction These Rules of Membership apply in respect of all Products purchased by a Member from Sigma (and any Program Partner) on or after 1 February 2017. The previously published
More informationPRESENTATION ON 2017 THIRD QUARTERLY RESULTS
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationSmall-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK
Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase
More informationAltria Group Inc. Ticker: MO
Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also
More informationSmall-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
More informationBrisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
More informationLAIDLAW & COMPANY Est. 1842
LAIDLAW & COMPANY London New York San Francisco Stamford Ft. Lauderdale EQUITY RESEARCH Company Report Mast Therapeutics (MSTX - $ 0.50) Vepoloxamer Pre-clinical Data to Be Presented at Sickle Cell Disease
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationTrend Focus. Nicotine patches vs. cigarettes. Figure 1. Global cigarette consumption by region (2012) 24%
Nicotine patches vs. cigarettes PT. Mirae Asset Sekuritas Indonesia Nur Marini +62-21-515-1140 (ext: 237) marini@miraeasset.co.id Nicotine patches and other forms of nicotine replacement therapy (NRT)
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationSponsors. Editors W. Christopher Scruton Stephen Claas. Layout David Brown
Sponsors University of Minnesota College of Veterinary Medicine College of Agricultural, Food and Environmental Sciences Extension Service Swine Center Editors W. Christopher Scruton Stephen Claas Layout
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationSingapore Exchange Limited 1Q FY2009 Financial Results
Singapore Exchange Limited 1Q FY2009 Financial Results 15 October 2008 Singapore Exchange 1 1Q FY2009 Financial Performance NPAT fell 35% from record 1Q FY2008 Operating profit flat compared to 4Q FY2008
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationAltria Group Inc (MO-NYSE)
March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00
More informationWntResearch. Pearls on a string. 3 September 2018 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Company announcements +32% +58% Pearls on a string has had troublesome times, but now everything seems to fall into place. With a new CEO in charge the phase II trials close to commencing in
More informationSmall-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014
Small-Cap Research December 17, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Auspex Pharmaceuticals Inc. ASPX SD-809 Hits
More informationscr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES
Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq
More informationSector Update. Rubber Glove. Robust Demand Spills Over to 2010
PP10551/10/2010(025682) 13 January 2010 Jason Yap +60 (3) 9207 7698 Jason.yap@osk.com.my Sector Update Rubber Glove MALAYSIA EQUITY Investment Research Daily News Robust Demand Spills Over to 2010 OVERWEIGHT
More informationSirtex Medical Ltd Buy
Research Sirtex Medical Ltd Buy Price: A$16.32 Price Target: A$20.50 ASX: SRX 21 April 2017 Sirtex Medical (SRX) is a global medical device company which targets cancer therapies, with its lead product
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationMDxHealth. Excellent Buy Opportunity. Research Note.
Research Note MDxHealth Excellent Buy Opportunity Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com Date: 29 February
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationMedivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationBVI Limited Partnership Hedge Funds: Calling Japan
BERMUDA BRITISH VIRGIN ISLANDS CAYMAN ISLANDS CYPRUS DUBAI HONG KONG LONDON MAURITIUS MOSCOW SÃO PAULO SINGAPORE conyersdill.com June 2012 BVI Limited Partnership Hedge Funds: Calling Japan Structuring
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationColoplast A/S. Investor Presentation 2005/06
Coloplast A/S Investor Presentation 2005/06 2 Coloplast in brief Coloplast s products and services help patients achieve greater independence from medical challenges in 4 areas, ostomy care, urology &
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, September 27, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Sep-5 Dec-5 Mar-6 Jun-6 Sep-6
More informationNATIONAL BANK OF POLAND
NATIONAL BANK OF POLAND RECENT TRENDS IN THE REAL ESTATE MARKET INTERNATIONAL CONFERENCE THE HOUSING PRICES IN ROMANIA - recent developments - Ph.D. Andrei RĂDULESCU Senior Economist Researcher, IWE, Romanian
More informationPortfolio Strategy Group
PSG's Weekly Chart Perspective Portfolio Strategy Group Report Date: Monday, November 15, 21 Daily Close UST 1 Year CMT 5 Year History 5. 4.5 4. 3.5 3. 2.5 2. US Recession Nov-5 Feb-6 May-6 Aug-6 Nov-6
More informationSAGE-547 s mechanism of action is already addressed by other drugs that are commonly used to treat SRSE patients
April 2016 Sage Therapeutics, Inc. (SAGE) Sell-Side Assumptions Are Wrong: Core Placebo Response Rate Assumption is Way Off and SAGE-547 Still Confers No Meaningful Benefit to SRSE Patients Following our
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationHemispherx Biopharma AMEX: HEB
Hemispherx Biopharma AMEX: HEB Re-commercialization Proceeds with some delay Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies
More informationChina Animal Vaccine Industry Report, Jun 2012
China Animal Vaccine Industry Report, 2011-2012 Jun 2012 STUDY GOAL AND OBJECTIVES This report provides the industry executives with strategically significant competitor information, analysis, insight
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationRussia Cardiac Assist Devices Market Outlook to 2021
Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for
More informationMDxHealth. Acceleration of payor coverage ConfirmMDx. Research Note.
Research Note MDxHealth Acceleration of payor coverage ConfirmMDx Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More information